RecruitingPhase 4NCT05201781

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Sponsor

Janssen Research & Development, LLC

Enrollment

295 participants

Start Date

Mar 9, 2022

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term safety follow-up study for patients who previously received a CAR-T cell therapy called ciltacabtagene autoleucel (cilta-cel) for multiple myeloma in another clinical trial. Researchers are monitoring participants for years after their treatment to track long-term outcomes. **You may be eligible if...** - You previously received at least one dose of cilta-cel in a company-sponsored clinical trial - You are willing and able to provide informed consent **You may NOT be eligible if...** - You did not receive cilta-cel in a company-sponsored study - You are unwilling to participate in long-term follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCilta-cel

Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.

Locations(50)

Mayo Clinic Cancer Center-Scottsdale

Phoenix, Arizona, United States

City of Hope

Duarte, California, United States

University of California San Francisco

San Francisco, California, United States

Stanford University Medical Center

Stanford, California, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University

Atlanta, Georgia, United States

Northwestern University

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

Kansas University Medical Center

Westwood, Kansas, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Washington University School Of Medicine

St Louis, Missouri, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Mount Sinai Medical Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

Froedtert Memorial

Milwaukee, Wisconsin, United States

UZ Gent

Ghent, Belgium

UZ Leuven

Leuven, Belgium

Peking University Third Hospital

Beijing, China

West China Hospital Si Chuan University

Chengdu, China

Fujian Medical University Union Hospital

Fuzhou, China

Sun Yat-sen University Cancer Hospital

Guangzhou, China

First Hospital, Zhejiang University Medical College

Hangzhou, China

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing, China

Jiangsu Province Hospital

Nanjing, China

Shanghai Changzheng Hospital

Shanghai, China

Ruijin Hospital Shanghai Jiao Tong University

Shanghai, China

Shanghai Fourth People s Hospital

Shanghai, China

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China

CHRU de Lille Hopital Claude Huriez

Nord, France

Hopital Saint Louis

Paris, France

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Nagoya City University Hospital

Nagoya, Japan

Japanese Red Cross Medical Center

Shibuya City, Japan

VU Medisch Centrum

Amsterdam, Netherlands

University Medical Center Groningen

Groningen, Netherlands

Clinica Univ. de Navarra

Pamplona, Spain

Hosp Clinico Univ de Salamanca

Salamanca, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05201781

Related Trials

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT0558361716 locations

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location